Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Onconova Appoints Ajay Bansal as Chief Financial Officer

Published: Wednesday, April 03, 2013
Last Updated: Wednesday, April 03, 2013
Bookmark and Share
Mr. Bansal has over 25 years of life sciences industry experience and most recently served as Chief Financial Officer at Complete Genomics.

“I am delighted to welcome Ajay to Onconova,” said Ramesh Kumar, Onconova’s Chief Executive Officer. “Ajay brings leadership experience relevant to all key aspects of Onconova’s corporate development, including financing, strategic planning, licensing, sales and marketing, and pricing. He will be an extremely valuable addition to the Onconova executive team as we transition to the later stages of development of rigosertib, our lead product candidate. I look forward to his contributions as we execute our business plan in 2013 and beyond.”

“I am excited to join Onconova at this important period in the Company’s development,” commented Mr. Bansal. “The Phase 3 study of rigosertib in patients with myelodysplastic syndromes is approaching full enrollment, and we are also advancing rigosertib in other indications. The potential benefit of rigosertib for the treatment of patients with both solid and hematological malignancies presents a significant opportunity, and I look forward to helping the Company meet its objectives for this compound and the rest of the pipeline.”

Mr. Bansal is a biotechnology and pharmaceutical industry veteran with leadership experience spanning the areas of finance, hedge fund management, equity research, mergers and acquisitions, post-merger integration, strategic planning, licensing, sales and marketing, pricing, and pharmacoeconomics. Before joining Onconova, Mr. Bansal served as CFO of Complete Genomics, a publicly-traded life science company. In this role he successfully raised $130 million. Complete Genomics was recently acquired by BGI. Prior to Complete Genomics, Mr. Bansal served as the CFO and EVP, Corporate and Business Development, at both Lexicon Therapeutics and Tercica, Inc. Tercica was acquired by Ipsen in 2008. He also served as the CFO of Nektar Therapeutics from 2003-2006. As the CFO of Nektar he successfully raised over $650 million.

Before his experiences as a biotechnology executive, he was a partner at Mehta Partners, LLC. In this role, Mr. Bansal provided strategic advisory services to the firm’s biotechnology and pharmaceutical clients. He also helped manage the firm’s investment business and coordinated its research efforts, focusing on mid-size and large biopharma companies. Earlier in his career, Mr. Bansal worked in strategy and marketing for Novartis Pharmaceuticals and held positions with leading consulting firms, such as McKinsey & Company. He received master’s degrees in both management and operations research from Northwestern University.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Onconova Announces Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer
Oral rigosertib progresses to phase 2 clinical trial in squamous cell head and neck cancers.
Wednesday, April 10, 2013
GVK Biosciences and Onconova Therapeutics Partner
Companies form novel joint development partnership to advance new drugs for cancer.
Thursday, January 10, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
A Diversity of Genomes
New DNA from understudied groups reveals modern genetic variation, ancient population shifts.
“Sixth Sense” May Be More Than Just A Feeling
The NIH Study shows that two young patients with a mutation in the PIEZ02 have problems with touch and proprioception, or body awareness.
Gene Could Reduce Female Mosquitoes
Virginia Tech researchers have found a gene that can reduce female mosquitoes over many generations.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Improving Crop Efficiency with CRISPR
New study of CRISPR-Cas9 technology from Virginia Tech shows potential to improve crop efficiency.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!